•  
  •  
 

Rehabilitation Practice and Science

Translated Title

以Celecoxib 治療血友病膝關節病變合併滑囊炎

Abstract

Introduction: Recurrent hemoarthrosis leads to synovitis, bone erosion, and subsequent hemoarthropathy in hemophilia. Few clinical trials have focused on the efficacy and adverse effects of nonsteroidal antiinflammatory drugs (NSAIDs), specifically cyclooxygenase-2-selective NSAIDs, in treating hemoarthropathy in patients with hemophilia. This study investigated the effect and safety of celecoxib in treating hemophilic arthropathy with synovitis. Materials and method: A total of 15 patients with hemophilic arthropathy were prescribed 200 mg of celecoxib twice per day for 30 days. Out come measurements regarding before and after treatment, joint range of motion, pain score (visual analogue scale), bleeding frequency, synovial thickness measured using ultrasonography, synovial vascularity measured using power Doppler ultrasonography, and 36-item short-form health survey (SF-36), were recorded to evaluate the efficacy and adverse effect of celecoxib. Result: After treatment with celecoxib for 30 days, the pain score (p＜ 0.001), bleeding frequency (p = 0.01), and SF-36 score (p=0.027) were statistically significant; however, synovial thickness, vascularity, and joint range of motion were not. Impaired liver function was only observed in one patient, and no significant adverse effects, such as gastrointestinal tract bleeding or other hemorrhage, occurred. Conclusion: Short-term use of celecoxib in treating hemophilic arthropathy with synovitis enables pain reduction and an improved quality of life. In addition, no significant increase in the risk of hemoarthrosis or other adverse effects was observed. Celecoxib is suggested for use before considering chemoablation or arthroscopic synovectomy.

Language

Traditional Chinese

First Page

207

Last Page

214

Download

Share

COinS